Vertex Pharmaceuticals and Genomics Extend $220 million Drug Development Partnership
VRTX Vertex Pharmaceuticals Inc
$536.45 +0.42%
View chart & analysis → - 1Vertex Pharmaceuticals and Genomics have agreed to extend their four-year drug development partnership.
- 2This agreement is a drug development partnership between Vertex Pharmaceuticals and Genomics with a potential value exceeding $220 million.
- 3In July of this year, there was a deal for the acquisition of Crinetics Pharmaceuticals by Vertex Pharmaceuticals valued at approximately $10 billion.
So what's the key point?
Vertex Pharmaceuticals and Genomics have decided to extend their agreement to develop new drugs for another four years. This agreement has a value of more than $220 million.
Source Pharmaceutical Technology · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.